HARBOUR ONCOLOGY LIMITEDActive

Company number 12166703Private limited companyIncorporated 2019

Key figures

£12,539+4.8%
Net assets 2024/25
+6.3%
Average annual growth 2019/20–2024/25
010 k20 k30 k2019/202020/212021/222022/232023/242024/25

Like most small UK companies, HARBOUR ONCOLOGY LIMITED does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.

Ratios

2024/25
Balance sheet structure
Current assetsFixed assetsLiabilitiesNet assets
020 k40 k60 k2019/202020/212021/222022/232023/242024/25
Filed accounts2019/20–2024/25
2020/212021/222022/232023/242024/25
Cash at bank and in hand28,22430,476———
Total assets31,88632,28641,86322,16730,806
Total liabilities——13,38210,94819,109
Net assets / total equity6,92520,48927,68111,95912,539
Average number of employees11111

A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.

Principal activity

Accounts 2025

86220

As described in the company's latest filed accounts.

Summary: HARBOUR ONCOLOGY LIMITED

Company

HARBOUR ONCOLOGY LIMITED is a private limited company registered with Companies House under company number 12166703. It was incorporated on 21 Aug 2019. Its status is active. The registered office is in Stourport-on-severn (DY13). Its nature of business (SIC 2007) is specialists medical practice activities (86220).

Accounts

The latest accounts in the database are for 2024/25 (period ending 31 Aug 2025); the company files micro-entity accounts. Net assets were £12,539, up 4.8% on the previous year. Total assets were £30,806 and total liabilities £19,109. The company had an average of 1 employee. Figures are available for 6 financial years (2019/20–2024/25).

Control and charges

One person with significant control is registered.

Filing deadlines

The next accounts are due by 31 May 2027. The next confirmation statement is due by 3 Sep 2027.